microRNA 4257 (miR-4257)

microRNA 4257 (miR-4257, hsa-mir-4257, MIR4257) is a small, non-coding RNA molecule classified as a microRNA, which plays a role in post-transcriptional gene regulation by binding complementary sequences in target mRNA transcripts, leading to mRNA degradation or translational repression[2][4][5]. While detailed mechanistic targets of miR-4257 remain understudied, clinical and experimental evidence shows that elevated expression of miR-4257 in tumors and plasma is associated with increased tumor growth, cell adhesion, and worse recurrence rates in colorectal cancer, and its upregulation has also been observed in non-small cell lung cancer patients with recurrence, supporting its exploration as a biomarker for prognosis[1][3]. miR-4257 is induced by inflammatory cytokines and may participate in cancer progression, particularly in malignancy and metastasis[1][3]. It is not considered a canonical therapeutic target such as a receptor, enzyme, or transporter; rather, it is a non-coding RNA primarily studied for its potential as a biomarker and its mechanistic role in cancer biology[2][4][5]. Clarification on correctness: - The entry "microRNA 4257" refers to a specific miRNA, not a protein or classical drug target (receptor, enzyme, etc.)[2][4][5]. - There is no evidence it interacts directly with drugs or has therapeutic drugs targeting it[6]. - No safety profile applies, as it is not a protein target but a regulatory RNA. - The scientific literature is limited regarding its detailed downstream mRNA targets, molecular mechanisms, or druggability[1][3]. - Therefore, although it is a molecule of strong interest for cancer biomarker research, it is not considered a therapeutic target in the traditional sense, and information may be sparse compared to well-characterized protein targets. Summary of missing/correctness: - Not a classical therapeutic target (is_target: false) - Limited information on mechanisms and no drugs directly targeting it (mechanism_of_action: null, interacting_drugs: null) - Used as a biomarker, primarily in cancer recurrence settings[3] - Not misspelled, but its entry as a "target" needs clarification (is_incorrect: true) per typical pharma/therapeutic databases[2][4][6]

Other names

hsa-mir-4257MIR4257